152 related articles for article (PubMed ID: 23571761)
1. Glucose corrected standardized uptake value (SUVgluc) in the evaluation of brain lesions with 18F-FDG PET.
Nozawa A; Rivandi AH; Kesari S; Hoh CK
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):997-1004. PubMed ID: 23571761
[TBL] [Abstract][Full Text] [Related]
2. Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes.
Nozawa A; Rivandi AH; Kanematsu M; Hoshi H; Piccioni D; Kesari S; Hoh CK
Nucl Med Commun; 2015 Jun; 36(6):573-81. PubMed ID: 25714806
[TBL] [Abstract][Full Text] [Related]
3. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
4. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
5. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET.
Lee SM; Kim TS; Lee JW; Kim SK; Park SJ; Han SS
Clin Nucl Med; 2011 May; 36(5):331-6. PubMed ID: 21467846
[TBL] [Abstract][Full Text] [Related]
6. Glucose-corrected standardized uptake value (SUV
Jahromi AH; Moradi F; Hoh CK
Am J Nucl Med Mol Imaging; 2019; 9(5):243-247. PubMed ID: 31772822
[TBL] [Abstract][Full Text] [Related]
7. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
[TBL] [Abstract][Full Text] [Related]
8. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
Sahlmann CO; Siefker U; Lehmann K; Meller J
Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
[TBL] [Abstract][Full Text] [Related]
9. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
[TBL] [Abstract][Full Text] [Related]
11. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.
Degirmenci B; Wilson D; Laymon CM; Becker C; Mason NS; Bencherif B; Agarwal A; Luketich J; Landreneau R; Avril N
Nucl Med Commun; 2008 Jul; 29(7):614-22. PubMed ID: 18528183
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET of common enhancing malignant brain tumors.
Kosaka N; Tsuchida T; Uematsu H; Kimura H; Okazawa H; Itoh H
AJR Am J Roentgenol; 2008 Jun; 190(6):W365-9. PubMed ID: 18492879
[TBL] [Abstract][Full Text] [Related]
14. Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake.
Bucerius J; Mani V; Moncrieff C; Rudd JH; Machac J; Fuster V; Farkouh ME; Fayad ZA
J Am Coll Cardiol; 2012 Jun; 59(23):2080-8. PubMed ID: 22651864
[TBL] [Abstract][Full Text] [Related]
15. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
Conrad GR; Sinha P
Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
[TBL] [Abstract][Full Text] [Related]
16. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
17. Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer.
Buvat I; Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P
Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1628-34. PubMed ID: 22710958
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET/CT for diagnosis of primary ovarian cancer.
Kitajima K; Suzuki K; Senda M; Kita M; Nakamoto Y; Onishi Y; Maeda T; Yoshikawa T; Ohno Y; Sugimura K
Nucl Med Commun; 2011 Jul; 32(7):549-53. PubMed ID: 21407140
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of solitary thyroid nodule on 18F-FDG PET/CT and high-resolution ultrasonography.
D'Souza MM; Marwaha RK; Sharma R; Jaimini A; Thomas S; Singh D; Jain M; Bhalla PJ; Tripathi M; Tiwari A; Mishra A; Mondal A; Tripathi RP
Ann Nucl Med; 2010 Jun; 24(5):345-55. PubMed ID: 20373060
[TBL] [Abstract][Full Text] [Related]
20. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]